GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Capex-to-Revenue

Cognetivity Neurosciences (Cognetivity Neurosciences) Capex-to-Revenue : 0.67 (As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Cognetivity Neurosciences's Capital Expenditure for the three months ended in Oct. 2023 was $-0.01 Mil. Its Revenue for the three months ended in Oct. 2023 was $0.02 Mil.

Hence, Cognetivity Neurosciences's Capex-to-Revenue for the three months ended in Oct. 2023 was 0.67.


Cognetivity Neurosciences Capex-to-Revenue Historical Data

The historical data trend for Cognetivity Neurosciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Capex-to-Revenue Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Capex-to-Revenue
Get a 7-Day Free Trial - - - - 1.53

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.09 1.33 0.27 0.67

Competitive Comparison of Cognetivity Neurosciences's Capex-to-Revenue

For the Health Information Services subindustry, Cognetivity Neurosciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's Capex-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Capex-to-Revenue falls into.



Cognetivity Neurosciences Capex-to-Revenue Calculation

Cognetivity Neurosciences's Capex-to-Revenue for the fiscal year that ended in Jan. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.052) / 0.034
=1.53

Cognetivity Neurosciences's Capex-to-Revenue for the quarter that ended in Oct. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.014) / 0.021
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (OTCPK:CGNSF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Cognetivity Neurosciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire 04-12-2019